^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:sabatolimab (MBG453) (TIM-3 antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2021
    Title:

    SABATOLIMAB PLUS HYPOMETHYLATING AGENTS (HMAS) IN PATIENTS (PTS) WITH HIGH-/VERY HIGH-RISK MYELODYSPLASTIC SYNDROME (HR/VHR-MDS) AND ACUTE MYELOID LEUKEMIA (AML): SUBGROUP ANALYSIS OF A PHASE 1 STUDY

    Published date:
    05/12/2021
    Excerpt:
    To explore sabatolimab+HMA safety/tolerability, sabatolimab dose interruption (>7 d delay), reduction…6/7 responders with TP53 mutation had complex karyotype….Sabatolimab+HMA showed favorable tolerability in MDS/AML…
    Secondary therapy:
    Hypomethylating agent